These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34285087)

  • 1. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
    Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
    Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
    Wang R; You J
    J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell state-dependent chromatin targeting in NUT carcinoma.
    Alekseyenko AA; Zee BM; Dhoondia Z; Kang H; Makofske JL; Kuroda MI
    Genetics; 2023 Jul; 224(3):. PubMed ID: 37119804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
    Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
    Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
    Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
    Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
    Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
    Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUT Is a Driver of p300-Mediated Histone Hyperacetylation: From Spermatogenesis to Cancer.
    Rousseaux S; Reynoird N; Khochbin S
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
    Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
    Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
    Yan J; Diaz J; Jiao J; Wang R; You J
    J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
    Shiota H; Elya JE; Alekseyenko AA; Chou PM; Gorman SA; Barbash O; Becht K; Danga K; Kuroda MI; Nardi V; French CA
    Mol Cancer Res; 2018 Dec; 16(12):1826-1833. PubMed ID: 30139738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
    French CA
    Pathol Int; 2018 Nov; 68(11):583-595. PubMed ID: 30362654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Gen Y; Muramatsu T; Inoue J; Inazawa J
    Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zheng D; Elnegiry AA; Luo C; Bendahou MA; Xie L; Bell D; Takahashi Y; Hanna E; Mias GI; Tsoi MF; Gu B
    Life Sci Alliance; 2024 Jul; 7(7):. PubMed ID: 38724194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of NUT midline carcinoma by epigenomic reprogramming.
    Schwartz BE; Hofer MD; Lemieux ME; Bauer DE; Cameron MJ; West NH; Agoston ES; Reynoird N; Khochbin S; Ince TA; Christie A; Janeway KA; Vargas SO; Perez-Atayde AR; Aster JC; Sallan SE; Kung AL; Bradner JE; French CA
    Cancer Res; 2011 Apr; 71(7):2686-96. PubMed ID: 21447744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.